Clinical Trial Update: Study of KRN951 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of the investigational agent KRN951 in patients with solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KRN951

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED